| Scorecard |
|---|
|
4 / 5 Stars
|
|
Lipper
5
5
5
4
2
|
|
Zacks Investment Research
2
(Buy)
|
|
Standard & Poor's
5 / 5 Stars
|
|
TheStreet.com
B-
(Buy)
|
Fund Holdings
Asset Allocation
| % Long | % Short | % Net | |
|---|---|---|---|
| Cash | 3.39 | 0.2 | 3.19 |
| Stocks | 38.3 | 0.0 | 38.3 |
| Bonds | 0.0 | 0.0 | 0.0 |
| Other | 0.01 | 0.0 | 0.01 |
| Foreign Bonds | 0.0 | 0.0 | 0.0 |
| Foreign Stocks | 58.5 | 0.0 | 58.5 |
| Convertible | 0.0 | 0.0 | 0.0 |
| Preferred | 0.0 | 0.0 | 0.0 |
Updated 03.31.2013
Top 10 Holdings
Performance as of 04.30.2013
Portfolio as of 03.31.2013
| Ticker | YTD Return % | % Net Assets | |
|---|---|---|---|
| Pfizer Inc | PFE | 16.19 | 3.22 |
| Roche Holding AG | RHHVF | 23.65 | 3.1 |
| Sanofi | SAN | --- | 3.01 |
| Imperial Tobacco Group PLC | IMT | --- | 2.95 |
| Johnson & Johnson | JNJ | 21.03 | 2.85 |
| Novartis AG | NVSEF | 17.5 | 2.83 |
| Coca-Cola Co | KO | 17.21 | 2.69 |
| Nestle SA | NSRGF | 9.65 | 2.46 |
| GlaxoSmithKline PLC | GLAXF | 20.09 | 2.38 |
| Royal Dutch Shell PLC Class B | RDSB | --- | 2.37 |
